Objective: The purpose of this study was to assess the effects of glucose fluctuation management on nerve function (The National Institute of Health Stroke Scale, NIHSS), life ability (Modified Ranking Scale, MRS), and quality of life (Stroke Impact Scale, SIS) in type 2 diabetes patients with the first episode of cerebral infarction.
Methods: This was a randomized control trial. 75 type 2 diabetes patients with the first episode of cerebral infarction were randomized into 2 groups: control group (n=37) with usual care, focused on A1c control, targeting A1C <7%, and intervention group (n=38), targeting both A1c <7% and daily glucose fluctuation (LAGE <80mg/dl).
Results: After 6 months, the data of 63 patients were finally analyzed (30 in the control group, 33 in the intervention group). There was no difference (P>0.05) in the reduction of A1c between 2 groups, but the reductions of LAGE (P=0.030), 1,5-AG (P=0.023), 2hPG (p=0.041), and LDL(p=0.046) were significantly different between two groups. The NIHSS score in intervention group was better than in the control (2.35±0.81 vs. 3.50 ±2.24, p=0.047 group. In terms of quality of life, there was no significant difference in total score of SIS between the two groups, but in the intervention group, the scores in the strength, hand function, and participation dimensions were higher than those in the control group (P=0.041, P=0.049, P=0.048, respectively). No significant difference was identified between two groups in scores of MRS and SDSCA.
Conclusions: Blood glucose fluctuation management can add values to A1c management in improving nerve function for type 2 diabetes patients with first episode of cerebral infarction.
J. Li: None.